<?xml version="1.0" encoding="UTF-8"?>
<app-group>
 <app id="app1-molecules-25-03822">
  <title>Supplementary Materials</title>
  <p>The following are available online: Figure S1: (
   <bold>a</bold>) Radius of gyration, (
   <bold>b</bold>) RMSD, and (
   <bold>c</bold>) RMSF for TMPRSS2 free protein. (
   <bold>d</bold>) Radius of gyration, (
   <bold>e</bold>) RMSD, and (
   <bold>f</bold>) RMSF for cathepsin L free protein, Figure S2: Superimposition of the snapshots at 120 ns, 140 ns and 160 ns of (
   <bold>a</bold>) TMPRSS2-T1 complex, (
   <bold>b</bold>) TMPRSS2-T2 complex, (
   <bold>c</bold>) TMPRSS2-T3 complex, (
   <bold>d</bold>) cathepsin L-C1 complex, (
   <bold>e</bold>) cathepsin L-C2 complex and (
   <bold>f</bold>) cathepsin L-C3 complex obtained from their respective MD simulation trajectories, Figure S3: Cartoon representation of the protein-ligand interactions of the phytochemical inhibitors of TMPRSS2. Interactions of TMPRSS2 residues with atoms of (
   <bold>a</bold>) T7, (
   <bold>b</bold>) T8, and (
   <bold>c</bold>) T9. The carbon atoms of the ligand are shown in green colour while the carbon atoms of the amino acid residues in TMPRSS2 are shown in cyan colour. TMPRSS2 residues interacting with the ligand atoms via hydrogen bonds or π-π stacking are labelled with the corresponding single letter residue code along with their position in the protein sequence. The hydrogen bonds and π-π stacking are displayed using yellow and red dotted lines, respectively, Figure S4: Cartoon representation of the protein-ligand interactions of the phytochemical inhibitors of cathepsin L. Interactions of cathepsin L residues with atoms of (
   <bold>a</bold>) C7, (
   <bold>b</bold>) C8, and (
   <bold>c</bold>) C9. The carbon atoms of the ligand are shown in green colour while the carbon atoms of the amino acid residues in cathepsin L are shown in cyan colour. Cathepsin L residues interacting with the ligand atoms via hydrogen bonds or π-π stacking are labelled with the corresponding single letter residue code along with their position in the protein sequence. The hydrogen bonds and π-π stacking are displayed using yellow and red dotted lines, respectively, Figure S5: Geometric criteria for the identification of protein-ligand interactions. (
   <bold>a</bold>) Hydrogen bond, (
   <bold>b</bold>) Chalcogen bond, (
   <bold>c</bold>) Halogen bond, (
   <bold>d</bold>) face-to-face π-π stacking, and (
   <bold>e</bold>) face-to-edge π-π stacking, Figure S6: Cartoon representation of the protein-ligand interactions of the known inhibitors of TMPRSS2 and cathepsin L. Interactions of TMPRSS2 residues with atoms of (
   <bold>a</bold>) nafamostat, and (
   <bold>b</bold>) camostat. Interactions of cathepsin L residues with atoms of (
   <bold>c</bold>) PC-0626568, (
   <bold>d</bold>) E-64d, and (
   <bold>e</bold>) GH4. The carbon atoms of the ligand are shown in green colour while the carbon atoms of the amino acid residues in TMPRSS2 or cathepsin L are shown in cyan colour. TMPRSS2 or cathepsin L residues interacting with the ligand atoms via hydrogen bonds or π-π stacking or halogen bonds are labelled with the corresponding single letter residue code along with their position in the protein sequence. The hydrogen bonds, π-π stacking and halogen bonds are displayed using yellow, red and black dotted lines, respectively, Figure S7: Superimposition of the docked pose of GH4 with cathepsin L obtained from AutoDock Vina (shown in green colour) and the pose of GH4 in the co-crystallized structure with cathepsin L (shown in red colour), Table S1: Top list of 96 phytochemical inhibitors of TMPRSS2. For each phytochemical, the table gives the symbol, docked binding energy, Pubchem identifier, common name, IUPAC name and SMILES, Table S2: Top list of 9 phytochemical inhibitors of cathepsin L. For each phytochemical, the table gives the symbol, docked binding energy, Pubchem identifier, common name, IUPAC name and SMILES, Table S3: Herbal sources of top 96 phytochemical inhibitors of TMPRSS2. For each phytochemical, the table gives the symbol, docked binding energy, common name and plant source. Plant sources which have been reported to have anti-viral or anti-inflammatory therapeutic use in traditional medicine literature are shown in bold and marked with an [*] sign, Table S4: The table lists the ligand binding site residues and non-covalent protein-ligand interactions namely, Hydrogen bond interactions, π-π stacking interactions of face-to-face type and face-to-edge type and Hydrophobic interactions that were identified from the docked protein-ligand complexes of the top 96 phytochemical inhibitors of TMPRSS2, Table S5: The table lists the ligand binding site residues and non-covalent protein-ligand interactions namely, Hydrogen bond interactions, π-π stacking interactions of face-to-face type and face-to-edge type and Hydrophobic interactions that were identified from the docked protein-ligand complexes of the top 9 phytochemical inhibitors of cathepsin L, Table S6: ADMET properties of the top list of 96 potential phytochemical inhibitors of TMPRSS2. For each phytochemical, the table gives the symbol, Pubchem identifier; several physicochemical properties such as Molecular weight in g/mol, LogP (Partition coefficient), MolarRefractivity, TPSA (Topological Surface Area) in Å
   <sup>2</sup>, Number of hydrogen bond acceptors, Number of hydrogen bond donors, Total number of atoms, Number of rotatable bonds, Shape complexity (fraction of carbon atoms that are sp
   <sup>3</sup> hybridized), Stereochemical complexity (fraction of carbon atoms which are stereogenic); several drug-likeness properties such as Lipinski RO5 filter (Lipinski’s Rule of 5 filter), QEDw (weighted quantitative estimate of drug-likeness), QEDuw (unweighted quantitative estimate of drug-likeness), Leadlikeness-number of violations predicted by SwissADME, Synthetic accessibility predicted by SwissADME; several absorption and distribution properties such as Solubility class predicted by SwissADME using ESOL method, Solubility class predicted by SwissADME using method by Ali et al., Solubility class predicted by SwissADME using Silicos-IT, Gasterointestinal absorption predicted by SwissADME, Skin permeation predicted by SwissADME (log Kp cm/s), Blood Brain Barrier permeation predicted by SwissADME, Blood Brain Barrier permeation predicted by vNNADMET, Bioavailability Score predicted by SwissADME; several metabolism properties such as P-glycoprotein substrate predicted by SwissADME, P-glycoprotein Substrate predicted by vNNADMET, P-glycoprotein inhibitor predicted by vNNADMET, Cytochrome P450 1A2 inhibitor predicted by SwissADME, Cytochrome P450 1A2 inhibitor predicted by vNNADMET, Cytochrome P450 2C19 inhibitor predicted by SwissADME, Cytochrome P450 2C19 inhibitor predicted by vNNADMET, Cytochrome P450 2C9 inhibitor predicted by SwissADME, Cytochrome P450 2C9 inhibitor predicted by vNNADMET, Cytochrome P450 2D6 inhibitor predicted by SwissADME, Cytochrome P450 2D6 inhibitor predicted by vNNADMET, Cytochrome P450 3A4 inhibitor predicted by SwissADME, Cytochrome P450 3A4 inhibitor predicted by vNNADMET, Human liver microsomal stability predicted by vNNADMET (HLM); several toxicity properties such as PAINS-Number of alerts predicted by SwissADME, Brenk-Number of alerts predicted by SwissADME, Drug-induced liver injury predicted by vNNADMET (DILI), Cytotoxicity predicted by vNNADMET, hERG Blocker predicted by vNNADMET, Mitochondrial toxicity predicted by vNNADMET (MMP) and Mutagenecity predicted by vNNADMET (AMES), Table S7: ADMET properties of the top list of 9 potential phytochemical inhibitors of cathepsin L. For each phytochemical, the table gives the symbol, Pubchem identifier; several physicochemical properties such as Molecular weight in g/mol, LogP (Partition coefficient), MolarRefractivity, TPSA (Topological Surface Area) in Å
   <sup>2</sup>, Number of hydrogen bond acceptors, Number of hydrogen bond donors, Total number of atoms, Number of rotatable bonds, Shape complexity (fraction of carbon atoms that are sp
   <sup>3</sup> hybridized), Stereochemical complexity (fraction of carbon atoms which are stereogenic); several drug-likeness properties such as Lipinski RO5 filter (Lipinski’s Rule of 5 filter), QEDw (weighted quantitative estimate of drug-likeness), QEDuw (unweighted quantitative estimate of drug-likeness), Leadlikeness-number of violations predicted by SwissADME, Synthetic accessibility predicted by SwissADME; several absorption and distribution properties such as Solubility class predicted by SwissADME using ESOL method, Solubility class predicted by SwissADME using method by Ali et al., Solubility class predicted by SwissADME using Silicos-IT, Gasterointestinal absorption predicted by SwissADME, Skin permeation predicted by SwissADME (log Kp cm/s), Blood Brain Barrier permeation predicted by SwissADME, Blood Brain Barrier permeation predicted by vNNADMET, Bioavailability Score predicted by SwissADME; several metabolism properties such as P-glycoprotein substrate predicted by SwissADME, P-glycoprotein Substrate predicted by vNNADMET, P-glycoprotein inhibitor predicted by vNNADMET, Cytochrome P450 1A2 inhibitor predicted by SwissADME, Cytochrome P450 1A2 inhibitor predicted by vNNADMET, Cytochrome P450 2C19 inhibitor predicted by SwissADME, Cytochrome P450 2C19 inhibitor predicted by vNNADMET, Cytochrome P450 2C9 inhibitor predicted by SwissADME, Cytochrome P450 2C9 inhibitor predicted by vNNADMET, Cytochrome P450 2D6 inhibitor predicted by SwissADME, Cytochrome P450 2D6 inhibitor predicted by vNNADMET, Cytochrome P450 3A4 inhibitor predicted by SwissADME, Cytochrome P450 3A4 inhibitor predicted by vNNADMET, Human liver microsomal stability predicted by vNNADMET (HLM); several toxicity properties such as PAINS-Number of alerts predicted by SwissADME, Brenk-Number of alerts predicted by SwissADME, Drug-induced liver injury predicted by vNNADMET (DILI), Cytotoxicity predicted by vNNADMET, hERG Blocker predicted by vNNADMET, Mitochondrial toxicity predicted by vNNADMET (MMP) and Mutagenecity predicted by vNNADMET (AMES).
  </p>
 </app>
</app-group>
